Application for Conditional Marketing Authorization to European Medicines Agency (EMA) by AB Science for Masitinib for the treatment of ALS. The application now validated by EMA was submitted based on the results of the phase II/III AB10015 study. The AB10015 trial was conducted on 394 ALS patients over 48 weeks as a randomized double-blind placebo-controlled trial.
Choosing the Right Patient for the Right ADC Beyond the Basics of Biomarker Testing
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed pivots from molecules to metrics. After a long run dissecting
